Benchmark Medical With Next Generation Methylated Liquid Live Detection Sequence Technology (AURORA)

The greatest feature of AURORA technology is that the innovative optimization of target enrichment can greatly improve the detection sensitivity and specificity of ultra-low-abundance CTDNA methylation signals, so that they can use fewer methylation markers to achieve the effectiveness of detection of early cancer, and improve the accuracy of detection models while avoiding the problem of model overfittingThe baseline team integrated a public database (e.gthe TCGA database) and a self-built methylation database of six major cancer species (more than 2,000 tissue samples and 4,000 plasma samples for genome-wide methylation analysis) to screen out the optimal methylation markers for the six cancers and to establish diagnostic modelsAURORA has higher sensitivity and specificity than similar technologies in the country - its overall performance in early screening in the three major cancer species (ROC-AUC) was 97.3% (lung cancer), 96.2% (breast cancer), 92.0% (colorectal cancer); Thebenchmark team is working with its Chinese partners to independently verify larger sample sizes of cancers such as lung, breast, and colorectal cancer in the real world, and will complete model optimization and testing of three other cancers (liver, stomach and esophageal) in the near futureWe believe that in the near future, the early sieve of multiple cancer species can be pushed into the 1000 RMB range, so that it can truly benefit everyoneoriginal title: Benchmark Medical with a new generation of methylated liquid activation detection sequence technology (AURORA) to help multi-cancer early screening into the era of universal benefits